Academy of Sciences of the Czech republic › About AS CR › AS CR Structure › Research institutes › ziva
Institute of Biotechnology of the ASCR, v. v. i.
Institute of Biotechnology of the ASCR, v. v. i.
Vídeňská 1083,
Praha 4, 142 20
Praha 4, 142 20
Phone: +420 241 063 613
FAX: +420 296 443 610
E-mail: btu-office@img.cas.cz
Chart: btu_chart.pdf
The institute was founded on January 1st, 2008 by transformation of the Division of Biotechnology of the Institute of Molecular Genetics AS CR, v.v.i. to an independent legal entity, a public research institution according to the Czech Act no. 341/2005.
The primary ambition of this new institute is to develop cutting-edge basic and oriented research on topics opening for diagnostic and therapeutic applications in human medicine.
In particular, the institute was established to serve as a nucleation center of BIOCEV, a joined Biotechnology and Biomedical Research Center of the Academy of Sciences with Charles University that is under preparation for being be built at Vestec near Prague by the year 2012, using the funds of the European Regional Development Funds under the Operational Program R&D for Innovation.
By 2009, two more groups will be established, focusing on computational and structural biology (i.e. modeling and solving of protein structures) and molecular markers and mechanisms of diabetic embryopathy.
The institute partners with the TATAA Biocenter Prague, co-organizing courses on gene expression profiling by qRT-PCR approaches. A particularly strong vocation of the new institute is to serve as a knowledge base for the nascent advanced biotech industry in the Czech Republic, where IBT is catalyzing the establishment of a Czech Biotech Cluster, centered around the biotechnology companies already having established their production sites at Vestec near Prague.
The nascent Czech Biotech Cluster is currently is open to all relevant human and veterinary vaccine producers, biotech companies using or producing recombinant proteins and/or focusing on tissue engineering, which are invited to join the undertaking.
Upon new recruitments in 2012, the IBT as part of BIOCEV in Vestec is expected to grow up to staff of 250 employees, aiming at conducting cutting-edge research in protein engineering, structural and cellular biology and immunology.
The primary ambition of this new institute is to develop cutting-edge basic and oriented research on topics opening for diagnostic and therapeutic applications in human medicine.
In particular, the institute was established to serve as a nucleation center of BIOCEV, a joined Biotechnology and Biomedical Research Center of the Academy of Sciences with Charles University that is under preparation for being be built at Vestec near Prague by the year 2012, using the funds of the European Regional Development Funds under the Operational Program R&D for Innovation.
By 2009, two more groups will be established, focusing on computational and structural biology (i.e. modeling and solving of protein structures) and molecular markers and mechanisms of diabetic embryopathy.
The institute partners with the TATAA Biocenter Prague, co-organizing courses on gene expression profiling by qRT-PCR approaches. A particularly strong vocation of the new institute is to serve as a knowledge base for the nascent advanced biotech industry in the Czech Republic, where IBT is catalyzing the establishment of a Czech Biotech Cluster, centered around the biotechnology companies already having established their production sites at Vestec near Prague.
The nascent Czech Biotech Cluster is currently is open to all relevant human and veterinary vaccine producers, biotech companies using or producing recombinant proteins and/or focusing on tissue engineering, which are invited to join the undertaking.
Upon new recruitments in 2012, the IBT as part of BIOCEV in Vestec is expected to grow up to staff of 250 employees, aiming at conducting cutting-edge research in protein engineering, structural and cellular biology and immunology.
Her parents are employed in the IMG (project BIOCEV). Because Katareeya originates from a “third country”, namely, Australia, according to the Czech legislation she is not entitled to healthcare support from the public healthcare insurance.
The cost of intensive therapy during first two months have already exceeded the limits of private insurance in the amount of 1,6 million CZK. All the cost now repose only on the girl’s parents.
More information...